The Delhi High Court’s decision in Array Biopharma Inc. v. Deputy Controller of Patents and Designs [C.A.(COMM.IPD-PAT) 37/2023] provides significant guidance on inventive step, the exclusions under Sections 3(d) and Section 3(i) of the Patent Act, and the standard of reasoning expected from the Patent Office when refusing combination patents involving multiple independently known active […]
